AstraZeneca: Latest News, Top Stories & Analysis

ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer

June 8, 2025June 7, 2025 - by Timothy Alexander

WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic …

Cancer / Regional

MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment

June 3, 2025June 1, 2025 - by Timothy Alexander

WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …

Cancer / Regional

AstraZeneca’s SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment

June 3, 2025June 1, 2025 - by Timothy Alexander

WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated …

Regional

AstraZeneca Showcases Oncology Breakthroughs Ahead of ASCO 2025

May 27, 2025May 26, 2025 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca is advancing its global efforts to transform cancer care by presenting pivotal data from its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual …

Regional

AstraZeneca’s BATURA Trial Highlights Breakthrough Results for Asthma Treatment

May 27, 2025May 25, 2025 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca has announced groundbreaking results from the BATURA Phase IIIb trial for AIRSUPRA (albuterol/budesonide), marking a significant advancement in asthma care. The anti-inflammatory rescue therapy demonstrated substantial …

Regional

AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBC

May 16, 2025May 16, 2025 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance …

Regional

ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer

May 14, 2025May 13, 2025 - by Timothy Alexander

WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab (THP), significantly improved pathologic complete response (pCR) …

Regional

AstraZeneca Reports Promising Phase III Trial Results for BREZTRI AEROSPHERE

May 9, 2025May 8, 2025 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise for its fixed-dose triple-combination therapy, BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or …

Regional

DESTINY-Breast09 Trial Demonstrates Promising Results for ENHERTU in Combination with Pertuzumab

April 30, 2025April 30, 2025 - by Timothy Alexander

WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly statistically significant and clinically meaningful improvement in …

Regional

ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial

April 28, 2025April 27, 2025 - by Timothy Alexander

WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …